Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Net Issuance of Common Stock
Zealand Pharma A/S
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Issuance of Common Stock
kr8.2B
|
CAGR 3-Years
122%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Net Issuance of Common Stock
-kr3.8B
|
CAGR 3-Years
-129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Issuance of Common Stock
€340.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
22%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Issuance of Common Stock
kr99.3m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
77%
|
CAGR 10-Years
-9%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Net Issuance of Common Stock
kr81.4m
|
CAGR 3-Years
165%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Net Issuance of Common Stock
kr88.9m
|
CAGR 3-Years
552%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
8.2B
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Net Issuance of Common Stock amounts to 8.2B DKK.
What is Zealand Pharma A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
64%
Over the last year, the Net Issuance of Common Stock growth was 437%. The average annual Net Issuance of Common Stock growth rates for Zealand Pharma A/S have been 122% over the past three years , 64% over the past five years .
You don't have any saved screeners yet